clov

Per-member revenue ~$17K/year mature. Three components: CMS risk-adjusted capitation (base PMPM), supplemental benefit utilization (pass-through), and Star quality bonuses (5% on 4-Star plans). The 2026 cohort skews PPO — slightly higher PMPM than HMO due to broader network access...

PPO emphasis — plan mix tilted toward PPO networks. Higher PMPM, broader appeal where members value network breadth. PPO members typically lower-acuity in first year vs HMO Special Needs Plans...

CLOV's competitive distance is not scale - it is a clinical decision-support layer backed by published outcomes: PCP use of Counterpart Assistant was associated with 18-22% fewer flu-related acute care events in COPD and CHF patients (Mar 19, 2026 study)...

Per CEO Toy's commentary alongside the 2026 guide, larger MA players (UNH, HUM, CVS, ELV) pulled back from unprofitable counties into 2025-26 as CMS rate notices tightened - opening whitespace for small focused payers...

The MA line has decades of share-growth runway before TAM saturation matters. CLOV is at ~0.3% share of a $500B+ market with 33M+ enrolled lives. The 2026 guide for 154-158K avg MA members (+46% YoY) implies CLOV can compound members without needing the MA market to grow...

Insurance GTM (consumer): MA runs on AEP (Oct 15 - Dec 7) plus Q1 Open Enrollment: Broker channels: independent agents and FMOs; the dominant new-member path DTC marketing targeted at age-65 turning population in footprint states Provider referrals from Clover's primary-care network Employer / group reach: selective group-MA opportunities Counterpart GTM (B2B): enterprise sales to payers and providers: First payer live on CMS Aligned Network (Mar 4, 2026) HealthEx interoperability partnership (Apr 7, 2026) - reduces integration friction HIMSS 2026 live demo targeting enterprise health IT buyers Outcomes-data-driven sales: the Mar 2026 study is the lead asset

Clover Assistant (internal): AI/ML clinical decision-support deployed to network PCPs at point of care - surfaces care gaps, chronic-condition flags, drug interactions, and recommendations tied to Clover claims + clinical data. Counterpart Assistant (external): the same engine, productized as SaaS for non-Clover payers and providers. Shared ML pipeline tuned on Clover's MA population - structurally the highest-acuity, highest-data-density book for COPD, CHF, diabetes...

Counterpart Health 2025 hard results (released 2026): >450% YoY growth in live third-party customer clinicians using the platform ~1,500 bps MCR differential for returning Clover members assigned to Counterpart Assistant PCPs vs non-CA cohort — direct medical-cost-ratio improvement at scale PPO Medicare Advantage plan #1 HEDIS score nationwide for the second consecutive year — independent quality validation Outcome study (Mar 19, 2026): PCP use of CA associated with 18-22% fewer flu-related acute care events for COPD/CHF patients Disease-specific reductions: all-cause hospitalizations CHF -18% / COPD -15%; 30-day readmissions CHF -25% / COPD -18% Compare to other healthcare AI plays (Tempus AI, Innovaccer, Color Health)...

Provider network density: the MA product is only as good as the PCP and specialist network it delivers. NJ/NY concentration is both asset (deep relationships, Clover Assistant deployment leverage) and constraint (concentration risk in CMS rate notices and county utilization shocks). PBM contracts: drug spend is meaningful inside MLR...

Provider network attrition: if PCPs shift carriers or exit MA, the Clover Assistant moat erodes with member access. Mitigation: depth of NJ/NY network plus Clover Assistant stickiness. PBM cost inflation: drug spend ahead of premium trend compresses MLR and pressures the 2026 Adj EBITDA guide ($50-70M)...

Q1-Q2 2026 — realized: May 6: ✓ Q1 2026 earnings — first-ever GAAP profit ($27.3M NI, $0.05 EPS); revenue $749M (+62%); MA 155,773 (+51%); FY26 guide reaffirmed Apr 2026: ✓ Counterpart HealthEx integration launched; CA platform live with hundreds of third-party clinicians Apr 2026: ✓ CMS 2027 MA Final Rate +2.48% 2026: ✓ #1 HEDIS PPO nationally (2nd consecutive year) Q2-Q4 2026 — forward catalysts: 2026 H1-H2: Counterpart first external paying SaaS contract (~55% probability, +/- 8-15% impact) Q2-Q4: Quarterly prints validate $2.9B+ FY26 revenue and $470-510M gross profit guide Oct 2026: CMS 2027 Star Ratings publication Q4 2026: 2027 MA AEP enrollment results Read: Q1 print was the major de-risking event; stock +42% to $3.84...

Post-Q1 2026 (May 2026): consensus 12M PT averages ~$2.90 (range $2.50-$3.20) on Hold — below $3.84 spot . Canaccord Buy $3.20; Leerink $2.50; UBS Neutral $2.75. Bull case anchors: FY26 guide high end + Counterpart SaaS contract + membership > 170K → ~1.0x sales → ~$6...

Three patterns reinforce each other: Sequential revenue acceleration. $462M → $478M → $497M is not a noisy pattern — each quarter set a new MA-pure-play high. Q4 mechanically closes the $1.92B FY25 print, anchoring the 2026 guide bridge...

Form 4 filings show the pattern typical of a small-cap recovery story: scheduled 10b5-1 sales by named executive officers as the share price reclaims trend, with no concentrated cluster sales suggesting management is signaling the top. Co-founders Vivek Garipalli (Executive Chairman) and Andrew Toy (CEO since Jan 2023) retain meaningful equity stakes per the most recent proxy disclosure, and have not publicly disclosed material changes to that posture. Read: No insider buy cluster (which would be the strongest bullish signal); no anomalous insider sell wave (which would be a tell)...

Three layers sit on top of each other in CLOV's holder base: Index passives (Vanguard, BlackRock, State Street). Standard small-cap and total-market index holdings. Mechanical buyers/sellers driven by index inclusion thresholds, not view...

Short interest in CLOV has historically run in a 15-25% of float band at peaks, reflecting structural skepticism on (a) MLR sustainability, (b) cash burn, and (c) the SPAC-era discount that hangs on names from that vintage. Current readings remain meaningfully elevated vs the typical small-cap healthcare comparable. Two asymmetries to note: Negative-catalyst beta is high...

Across these analogs the same pattern repeats. Small focused MA payers can earn premium multiples — the HUM 2010s precedent — once profitability is proven and Stars hold. The AI/tech overlay (ALHC, OSCR with care management; the Tempus/Innovaccer comp set on the SaaS side) acts as a multiplier on the multiple, not a substitute for the underlying insurance economics...

Profile: Stanford CS; ex-Google Cloud and Android for Work; founder of Divide (acq. Google). Joined Clover as CTO, promoted to President, assumed CEO Jan 2023 when Garipalli moved to Executive Chairman...

What happened: CFO Peter Kuipers stepped down effective March 30, 2026 (announced via 8-K Apr 1). Disclosure stated departure does not reflect any disagreement on operations, policies, or practices. Kuipers remains in advisory role through April 24, 2026 for transition handoff...

CMS rate notices set the ceiling. The annual MA Advance Notice and Final Rate Notice (Jan/Apr each year) are the single largest macro variable for CLOV. Every basis point of effective benchmark rate change flows through to revenue and — because cost-of-care is largely fixed in the short run — to Adj EBITDA...

CLOV is the kind of name that lights up on three modern quant overlays simultaneously: "Profitability turnaround" screens. Negative-to-positive Adj EBITDA + first GAAP-profit guide is the canonical setup these screens look for. Funds running this factor were structurally underweight CLOV pre-Feb 2026; the print mechanically pulls them in...

Generic equity factors miss most of what drives CLOV. The right exposure decomposition uses payer-specific factors: MA reimbursement factor. CMS rate notice cycle drives a meaningful portion of variance — shared with HUM, UNH (MA segment), ELV (MA segment), but not OSCR (exchange-skewed) or ALHC (similar pure-play exposure)...

CLOV trades like a high-vol small-cap healthcare name, not like a large-cap insurer. 30-day IV typically prints in the 60-90% band, often above realized vol — the structural retail/momo bid keeps option demand persistent. Two factors push IV higher: Earnings cycles reliably add 15-30 IV points in the 1-2 weeks pre-print, then collapse on the announcement...

Long calls into the May 6 print: avoid. IV will be at or near cycle highs. Even a directionally correct call typically loses on the IV crush post-event...

Q1 FY2026 print — May 6 — the binary near-term catalyst. First read on whether the +46% member growth bid pricing holds; first read on cost-of-care trajectory under the new acuity mix; first opportunity for management to reaffirm or tighten the FY26 guide. The market is pricing roughly a 12-18% one-day move based on current ATM straddle pricing in this IV regime...

GAAP reporting clean. Income statement, balance sheet, and cash flow reconcile across periods. SPAC-era restatements are behind the company; recent 10-Ks filed on time without material comment letters...

The wrong frame: P/E. CLOV's FY25 GAAP NI is $(85.5M); FY26 GAAP NI is guided to a slim $0-20M. P/E either undefined or unreliable around an inflection — it tells you nothing about whether the inflection is real...

Yes — the locked $4.50 PT sits squarely inside the SOTP equity range. $4.50 × ~531.7M shares = ~$1.86B equity value, which is above the SOTP midpoint (~$1.6B) but well within the upper half of the range ($1.1-2.1B). It assumes: Insurance core in the upper half of its 18-25x band on FY26 Adj EBITDA — reasonable if the +49% revenue / +46% member growth holds and MLR stays disciplined...